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ABSTRACT The lack of a calcium channel agonist (e.g., BayK8644) for CaV2 channels has impeded their investigation.
Roscovitine, a potent inhibitor of cyclin-dependent kinases 1, 2, and 5, has recently been reported to slow the deactivation of P/Q-
type calcium channels (CaV2.1). We show that roscovitine also slows deactivation (EC50 ;53 mM) of N-type calcium channels
(CaV2.2) and investigate gating alterations induced by roscovitine. The onset of slowed deactivation was rapid (;2 s), which
contrasts with a slower effect of roscovitine to inhibit N-current (EC50 ;300 mM). Slow deactivation was speciﬁc to roscovitine,
since it could not be induced by a closely related cyclin-dependent kinase inhibitor, olomoucine (300 mM). Intracellularly applied
roscovitine failed to slow deactivation, which implies an extracellular binding site. The roscovitine-induced slow deactivation was
accompanied by a slight left shift in the activation-voltage relationship, slower activation at negative potentials, and increased
inactivation. Additional data showed that roscovitine preferentially binds to the open channel to slow deactivation. A model where
roscovitine reduced a backward rate constant between two open states was able to reproduce the effect of roscovitine on both
activation and deactivation.
INTRODUCTION
The study of L-type calcium channel (CaV1 family) gating
and permeation has been greatly facilitated by drugs (e.g.,
BayK8644,1202–791) that increase channel open time over
a wide range of voltages. However, such drugs are inef-
fective toward the CaV2 family of calcium channels (P/Q-
type, N-type, and R-type), which has been one factor limiting
studies of these channels. This changed recently with a study
by Yan et al. (1) showing that the cyclin-dependent kinase
(cdk) inhibitor roscovitine slowed the deactivation of high
voltage-activated calcium channels that were insensitive to
L-channel blockers. Interestingly the effect of roscovitine
did not appear to involve cyclin-dependent kinases since
intracellular roscovitine was ineffective and calcium current
deactivation was slowed by roscovitine in neurons lack-
ing activated cdk5 (the dominant neuronal cdk) (2). The
roscovitine effect was blocked by v-conotoxin MVIIC
(vCMVIIC), which led the authors to conclude the affected
channels were P/Q-type (1). However, the micromolar
concentrations of vCMVIIC used in that study also block
N-type channels (3,4). An additional issue not addressed by
the original publication was how roscovitine inﬂuenced
channel gating to slow deactivation. We demonstrate that
roscovitine slows deactivation of N-type calcium channels
by binding to the open state, and develop a Markov model
that reproduces the kinetic effects of roscovitine, which in-




Paravertebral sympathetic ganglia were isolated from adult bullfrogs (Rana
catesbeiana) and neurons were dissociated with collagenase/dispase di-
gestion and trituration (5–7). The method of sacriﬁce was approved by the
Institutional Animal Care and Use Committee. Cells were maintained in
L-15 medium supplemented with 10% fetal bovine serum and penicillin/
streptomycin at 4C until use (usually 2–14 days).
Electrophysiology
Neurons were voltage-clamped using the whole-cell conﬁguration of the
patch-clamp technique. Pipettes were pulled from Schott 8250 glass (Garner
Glass, Claremont, CA) on a Sutter P-97 puller (Sutter Instruments, Novato,
CA). Series resistance ranged from 1.3 to 2.5 MV and was compensated at
90–95%. Currents were recorded using an Axopatch 200A ampliﬁer (Axon
Instruments, Foster City, CA) and digitized with a MacAdios II analog-
digital converter (GW Instruments, Somerville, PA). Experiments were
controlled by a Macintosh Quadra 800 computer (Apple Computer, Cupertino,
CA) running S3 data acquisition software written by Dr. Stephen Ikeda
(National Institutes of Health, National Institute on Alcohol Abuse and
Alcoholism, Bethesda, MD). Leak current was subtracted online using a P/4
protocol. All recordings were carried out at room temperature. Whole-cell
currents were digitized at 50 kHz after analog ﬁltering at 10 kHz, except for
envelope tail and triple pulse inactivation protocols that were digitized at
10 kHz after analog ﬁltering at 10 kHz.
Action potential waveforms (Fig. 8 a) were generated by a series of
voltage ramps that reproduce the bullfrog sympathetic neuron action po-
tential (8). The following is a list of the voltage range and duration of the
nine voltage ramps used in this waveform: 60 to 25 mV in 1.1 ms, 25
to137 mV in 0.5 ms (the fast rising phase),137 to138 mV in 0.1 ms,138
to137 mV in 0.1 ms,137 to 70 mV in 1.5 ms (the falling phase), 70 to
79 mV in 0.5 ms, 79 to 80 mV in 1 ms, 80 to 81 mV in 1 ms, and
81 to 60 mV in 11 ms (the after-hyperpolarization phase).
Solutions
The internal solution contained 61.6 mM NMGCl, 6.0 mM MgCl2, 14 mM
CreatinePO4, 2.5 mM NMGHEPES, 5 mM Tris2ATP, 10 mM
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NMG2EGTA, and 0.3 mM Li2GTP. The extracellular solution contained
117.5 mM NMGCl, 10 mM NMGHEPES, and 3 mM BaCl2. In some
external solutions 3 mM BaCl2 was replaced by either 10 mM CaCl2 or 30
mM BaCl2. The NMGCl concentration of these solutions was reduced to
maintain osmolarity, which was 240 mOsm for the external solutions and
200 mOsm for the internal solution. All solutions were titrated to pH 7.2
with NMG base. Test solutions were applied from a gravity-fed perfusion
system with seven inputs and a single output. The minimum exchange time
for this system was ;2 s.
Data analysis
Data were analyzed using Igor Pro (WaveMetrics, Lake Oswego, OR)
running on a Macintosh computer. Step currents were measured as the av-
erage of 10 points at the end of the 10-ms voltage step. Tail currents were
measured as the average of three points starting 0.3 ms into the repolarizing
pulse and late tail currents were measured the same way, beginning 2.5 ms
into the repolarizing pulse. The late tail current was used as an index of the
roscovitine effect and the time was chosen to be $33 the fast deactivation
time constant (tD). Activation t (tA) was estimated by ﬁtting a single-
exponential function to the current after a 0.3-ms delay (9). The value tD was
estimated from either single- or double-exponential ﬁts to tail currents
starting 0.3 ms into the repolarizing step. Control tail currents and tail
currents in roscovitine concentrations $100 mM were ﬁt using a single
exponential. Tail currents in roscovitine concentrations ,100 mM were ﬁt
using a double exponential with one t ﬁxed to control and the other t ﬁxed
to that measured in 100 mM roscovitine. In addition, envelope tail currents in
roscovitine were ﬁt with double exponentials with t s ﬁxed to control and
100-mM roscovitine (after a 10-ms step to 170 mV). The voltage
dependence of deactivation was determined by ﬁtting a single-exponential
equation to the tD-voltage relationship. Group data were calculated as mean
6 SD throughout the article. Paired t-test was used for in-cell comparison.
Computer simulations
Simulated currents were generated using Axovacs 3 (written by Stephen W.
Jones, Case-Western Reserve University) running on a Dell Inspiron 5150
computer (Dell Computer, Round Rock, TX). Voltage-dependent rate
constants (kx) in the model were calculated from
kx ¼ Ax expððV  CxÞzxF=RTÞ; (1)
where Ax is the rate constant at the characteristic voltage (Cx), zx is the charge
moved, and R, T, and F are the gas constant, absolute temperature, and Faraday’s
constant, respectively. Currents were simulated in response to both voltage
steps and an action potential. The action potential (Fig. 8 b) was generated
in Axovacs by combining Hodgkin-Huxley m3h sodium current and n4
potassium current models with our N-channel model. The N-channel con-
ductance was reduced to 1/400th of that of the sodium and potassium chan-
nels so that the shape of the Hodgkin-Huxley action potential (AP) was not
altered by the inclusion of the N-channel model. The ionic conditions for the
AP simulation were [Na1]o¼150, [Na1]i¼ 10, [K1]o¼ 5, and [K1]i¼ 140.
Chemicals
All experiments utilized R-roscovitine that was obtained from Calbiochem
(La Jolla, CA). Olomoucine was obtained from LC Labs (Woburn, MA). All
other chemicals were obtained from Sigma (St. Louis, MO). Control
solutions contained up to 0.6% DMSO to control for the DMSO concen-
tration of roscovitine and olomoucine solutions. For experiments using a
range of roscovitine concentrations (e.g., dose-response measurements), the
DMSO concentration of all solutions was set to that in the solution with the
highest roscovitine concentration. The DMSO in the control solutions had
no effect on the whole-cell calcium currents.
RESULTS
To determine if roscovitine could affect N-type channels we
utilized bullfrog sympathetic neurons in which N-channels
generate ;90% of the whole-cell calcium current (7,10).
Thus, large roscovitine effects can be attributed to
N-channels (11,12). Fig. 1 shows two roscovitine effects
on N-current. The initial effect was a slowing of deacti-
vation, which was followed by a slower inhibition that can be
observed in the step current. The roscovitine effect on de-
activation was quantiﬁed by measuring tail current (at 2.5
ms) after fast deactivation was nearly complete (Fig. 1). This
roscovitine effect is nearly complete within ;5 s after ini-
tiating application (3-s interval between steps). On the other
hand, step current inhibition is still incomplete at the end of
the 60-s application. The different time courses for these two
effects suggest they are mediated by distinct mechanisms.
This idea was supported by applying the cdk inhibitor
olomoucine (300 mM), which inhibited N-current (196 4%,
n ¼ 4), but failed to induce slow deactivation (change in late
tail current ¼ 6 6 5%) (Fig. 1). Distinct mechanisms for
slow deactivation and inhibition were further supported by
their different dose-response relationships, which were
measured during roscovitine applications ranging from 1 to
300 mM (Fig. 2). The roscovitine-induced slow deactivation
data were ﬁt with a single-site binding isotherm to obtain the
concentration yielding the half-maximal response (EC50),
which was 52.9 6 15.8 mM (mean 6 SD) from ﬁve cells.
From the same cells, the EC50 for inhibition was 294.1 6
173.8 mM. Unfortunately, the duration of roscovitine
FIGURE 1 Roscovitine (Rosc) slows N-channel deactivation, but the
closely related cdk inhibitor olomoucine (Olo) does not. (A) Currents
generated in a 3 mM Ba21 external solution show a decrease in step current
amplitude (open squares) and a slowing of tail current deactivation in
response to 100-mM roscovitine, but only the decreased step current in
response to 300-mM olomoucine. Slow deactivation is measured as the
amplitude of the late tail current (solid circles). (B) Currents before and upon
recovery from roscovitine and olomoucine are shown (thin lines) along with
the roscovitine- and olomoucine-affected currents (thick lines) in the top and
bottom panels, respectively. All data from the same cell. The // in A indicates
an approximately 3.5-min gap.
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application in this set of experiments was too short to reach
steady state for the inhibition of N-current. Thus, additional
experiments measured inhibition at the end of longer
roscovitine applications ($3 min), and the ﬁtting of these
data yielded an EC50 ¼ 140 mM for the inhibition of step
current (n ¼ 3–7, not shown). However, recovery of current
after these long roscovitine applications was often poor,
which complicated the interpretation of inhibition induced
by roscovitine. This poor recovery likely resulted from run-
down of calcium current, which was difﬁcult to control for
because of the long drug applications. Thus, the slow develop-
ment of inhibition complicates its accurate measurement, but
clearly distinguishes inhibition from slowed deactivation.
The concentrations required to obtain N-current effects
appear high compared to the published afﬁnities of
roscovitine for cdk 1, 2, and 5 (IC50 ; 0.16–0.7 mM) (2).
However, these values were obtained in low concentrations
of ATP (1 mM), which competes with roscovitine for
kinase binding (13). At physiological ATP levels, IC50 for
roscovitine block of cell division (cdk block) is ;40 mM
(14), which is similar to the EC50 we measure for slow
deactivation. In addition, other kinases such as extracellular
signal-regulated kinase 1, and glycogen synthase kinase 3
(IC50; 30 and 130 mM, respectively; see Ref. 2) have lower
afﬁnity for roscovitine, which could make them candidates
for mediating roscovitine-induced N-current inhibition
(EC50 . 100 mM). We tested for possible kinase involve-
ment by introducing 100 mM roscovitine into the pipette
solution to inhibit intracellularly located kinases. No slowing
of deactivation or excessive current reduction (inhibition)
was observed during whole-cell dialysis of up to 30 min with
roscovitine (n ¼ 5; not shown). In addition, the extracellular
application of 100 mM roscovitine induced a 6.6 6 3.0-fold
increase in late tail current in cells dialyzed with roscovitine
compared to 7.86 4.8-fold increase in control cells dialyzed
with 0.2% DMSO (n ¼ 4 ns, not signiﬁcantly different).
Thus, internal roscovitine failed to abrogate the ability of
extracellularly applied roscovitine to slow N-channel de-
activation, which suggests that kinase inhibition is not in-
volved in roscovitine’s effect on calcium channel gating (1).
The step current inhibition induced by externally applied
roscovitine (100 mM) was extremely small in this set of
experiments, 10.4 6 14.3% with intracellular roscovitine
versus 0.6 6 2.8% with intracellular DMSO control cells
(n¼ 4 ns). Thus, these experiments failed to resolve the pos-
sibility that kinases mediate roscovitine-induced N-current
inhibition.
The inability of olomoucine to slow deactivation further
supports the absence of kinase involvement (see Ref. 1, Fig.
1). Thus, slow deactivation appears to be speciﬁc for
roscovitine. However, N-current inhibition, which is induced
by both roscovitine and olomoucine, could be mediated by
kinase block. Further work is needed to test possible kinase-
mediated inhibition. These data together with different time
courses and EC50 for inhibition versus slow deactivation
point to distinct mechanisms for these roscovitine effects.
For this reason, we focus the remainder of this article on the
effect of roscovitine to slow N-current deactivation.
Roscovitine effects on N-channel kinetics
We examined N-current kinetics and steady-state voltage
dependence to investigate gating changes associated with
slow deactivation. Analysis of N-current kinetics was carried
out in 100-mM roscovitine, which induced slow deactivation
in the majority of N-channels, but only inhibited a relatively
small percentage of channels. Steady-state current measure-
ments (Fig. 3, a and b) showed a slight left-shift in voltage
dependence of N-channel activation. This shift was quanti-
ﬁed by ﬁtting double Boltzmann equations to the activation-
voltage relationship (activation curve; Fig. 3 b). The major
component (slope ¼ 7.2 mV) had an average shift in the
FIGURE 2 Dose-response relationships for the roscovitine-induced slow
deactivation and step current inhibition. (A) Step current (upper panel) and
late tail currents (lower panel) show the inhibition and slowed deactivation
effects of roscovitine, respectively. The currents were measured as described
in Materials and Methods. Note the slow inhibition of the late tail current
after the initial enhancement during 300-mM roscovitine. (B) Example
currents from the time course shown in A. The control currents are from the
step just before roscovitine application and the currents in roscovitine (thick
traces) are shown just before switching back to the control solution, except
for 300-mM roscovitine, which shows the current at peak enhancement of
the late tail current (;9 s into the roscovitine application). (C) The maximal
late tail enhancement (solid circles) and step current inhibition (open
squares) from the same cell shown in A and B are plotted versus roscovitine
concentration. The smooth lines are ﬁts using single-site binding isotherms
to yield the indicated half-maximal concentration (EC50).
Slowed N-Channel Deactivation 1683
Biophysical Journal 89(3) 1681–1691
half-activation voltage (V1/2) of 3.5 6 0.8 mV (n ¼ 7,
p , 0.01 using paired t-test). Even though this shift was
small it was consistent, in that it was observed in all seven
cells examined. The shift was fully reversible and could also
be observed in the current-voltage relationship (Fig. 3 a),
which led us to believe it is a real effect of roscovitine. The
steepness of the activation curve does not appear to change in
roscovitine (Fig. 3 b).
N-current activation was slowed most obviously at
hyperpolarized voltages (Fig. 3, c and d). The activation t
(tA) was quantiﬁed by ﬁtting activation with a single-
exponential function after a 0.3-ms delay (9). This method
revealed a roscovitine-induced increase in tA at negative
voltages that decreased monotonically with depolarization.
The tA in roscovitine was compared to the average tA before
and upon recovery from roscovitine and showed an increase
of 63% at 30 mV, 22% at 10 mV, 10% at 110 mV, and
6% at 130 mV (n ¼ 5, p , 0.01 paired t-test for each
voltage, except 130 mV where p . 0.05 ns). The larger tA
were consistently measured from roscovitine currents at
voltages ,120 mV in each of the ﬁve cells examined. The
time course for the roscovitine-induced increase in tA is simi-
lar to that observed for the enhancement of late tail current
(not shown), which supports its association with slowed
deactivation and not with the inhibitory effect of roscovitine.
The most prominent kinetic effect of roscovitine was to
slow N-channel deactivation (Fig. 4). Roscovitine increased
tD at each voltage examined, but it also decreased the
voltage dependence of the tD so that deactivation kinet-
ics could be resolved over a wider range of voltages. The
voltage dependence of tD was measured by ﬁtting a single-
exponential equation to the tD-voltage relationship to obtain
the tD voltage constant (n), which represents the DV for an
e-fold change in tD. The mean n in control (average of
control and recovery from roscovitine) was 26.06 2.0 mV
compared to n ¼ 67.2 6 11.6 mV in 100-mM roscovitine
(n ¼ 7, p , 0.01 paired t-test). Thus, a reduction in the
voltage dependence of deactivation appears to be a major
effect of roscovitine.
The ﬁnal kinetic process investigated was inactivation.
The main mechanism for N-channel inactivation over 500-
ms voltage steps has been attributed to inactivation from
intermediate closed-states (15,16), which has recently been
referred to as U-type inactivation, because of the U-shaped
voltage dependence (17) (Fig. 5 c). Using a triple pulse
protocol (20 ms prepulse, 500 ms inactivating pulse and 20
ms postpulse), we found that inactivation at 0 mV was
increased from 27.3 6 3.7% to 51.3 6 3.7% by 100-mM
roscovitine (Fig. 5, a and c). Inactivation in roscovitine still
declined with depolarization .0 mV, which is characteristic
of a U-type mechanism (Fig. 5 c). Interestingly, roscovitine
failed to affect inactivation at voltages hyperpolarized to
activation (compare Fig. 5, b and c). One explanation for this
phenomenon is that roscovitine preferentially binds to open
channels to affect gating.
Roscovitine preferentially binds to the open state
We tested the idea that roscovitine binds to open channels by
using an envelope tail protocol to measure the time-course of
the development of slowed deactivation in roscovitine (Fig.
6). The prediction is that roscovitine-induced slow de-
activation should become larger with longer open channel
durations. The tail current (at 30 mV) in control was
quantiﬁed by ﬁtting with a single exponential, and a plot of
the ﬁt amplitude versus the 170 mV step duration increased
FIGURE 3 Roscovitine inducessmall
changes in N-current activation. The
effect of 100-mM roscovitine (solid
circles) is shown on the current-voltage
relationship (A), the activation curve
measured from tail currents (B), and tA
(C) from a representative cell. The solid
lines in B are double Boltzmann ﬁts to
the tail current activation curve. For the
ﬁrst Boltzmann, the V1/2 is 18.7,
20.9, and 17.3 mV, and the slope is
e-fold for 7.0, 7.5, and 7.5 mV for
control, roscovitine, and recovery, re-
spectively, and for the second Boltz-
mann the respective values are V1/2 ¼
21.7, 30.5, and 23.6, and slope ¼ 9.8,
12.2, and 10.4. For each ﬁt the frac-
tional amplitudes were held at 0.9 and
0.1 for the ﬁrst and second components,
respectively. (D) Currents from the
same cell used for A–C showing the
slower activation at hyperpolarized voltages, the increased inhibition at more depolarized voltages, and slower deactivation after all voltage steps. The asterisks
indicate current in roscovitine and the dashed current traces (10 to 130 mV) are scaled roscovitine currents shown to permit comparisons of activation
between control (thin traces) and roscovitine currents. Currents after recovery from roscovitine are not shown, but recovery is shown in A–C. Outward currents
at the onset of the depolarizing step have been blanked. These data were recorded in 3 mM Ba21.
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monotonically as expected for channel activation (Fig. 6,
a and c). The tail current in roscovitine was quantiﬁed by
ﬁtting with double-exponential equations to obtain the
amplitude of the fast and slow components of deactivation.
The amplitude of each component in roscovitine was plotted
with that from control currents in Fig. 6 c. Brief steps (,1
ms) in 100-mM roscovitine activate channels that primarily
deactivate rapidly, as in control. However, the amplitude of
this control-like component peaks at ;1 ms and declines
with increasing step duration. This decline is accompanied
by an increase in the amplitude of slowly deactivating cur-
rent, which is consistent with open channels being converted
from control to roscovitine-bound. A second prediction of
the open-state binding hypothesis is that development of
slow tail current should depend on roscovitine concentration.
As predicted, the development of slowly deactivating current
was slower with lower roscovitine concentrations (Fig. 6 d).
FIGURE 4 Roscovitine reduces the voltage dependence of deactivation.
All data shown are from a representative cell. (A) tD measured from single-
exponential ﬁts to tail currents is plotted versus the tail voltage. Currents
were activated by a 15-ms step to 120 mV, and the duration of the
repolarization step was 20 ms. The y axis was log-transformed to highlight
the decrease in deactivation voltage dependence. The smooth lines are
single-exponential ﬁts from which the voltage constant (n) can be
determined. In control and recovery n ¼ 26.3 mV and 28.9 mV,
respectively. n increased to 55.7 mV in 100-mM roscovitine. (B) Currents
in control and after recovery from roscovitine are shown at two tail voltages
(40 and 80 mV). The recovery current is scaled to match that of control
to facilitate comparison of the deactivation kinetics. The smaller scale value
(1.2 nA) refers to the recovery current. (C) Tail currents in 100-mM
roscovitine can be resolved to voltages as negative as 160 mV. Note that
deactivation at 160 mV in roscovitine is slower than that at 80 mV in
control.
FIGURE 5 Roscovitine increases N-channel inactivation. (A) A triple
pulse protocol was used to examine the effect of roscovitine on inactivation.
The prepulse and postpulse were 20-ms steps to 0 mV, whereas the 500-ms
inactivation pulse was to voltages ranging from 80 to 180 mV (20-mV
increments). The increased inactivation induced by 100 mM roscovitine can
be observed during the 500-ms step to 0 mV. The external solution contained
30 mM Ba21. (B) A plot of peak current measured during the 500-ms step
versus the step voltage. The peak current was measured as the average62.5
ms around the peak. (C) The ratio of the postpulse current to prepulse current
is plotted versus the inactivation step voltage. This relationship in control
shows the characteristic U-shaped voltage dependence of N-current
inactivation. The addition of 100-mM roscovitine increased inactivation at
voltages .40 mV. The voltage-generating maximal inactivation did not
appear to be altered by roscovitine. Control was calculated as the average of
the post-/pre- ratio before and upon recovery from roscovitine. The data in
all panels are from the same cell.
Slowed N-Channel Deactivation 1685
Biophysical Journal 89(3) 1681–1691
This concentration-dependence was quantiﬁed by ﬁtting
single-exponential equations (after a 0.3-ms delay) to the
development time-course measured in three roscovitine con-
centrations. A plot of the inverse envelope t versus roscovitine
concentration was linear, and the data were ﬁt with the equa-
tion
1=t ¼ kon½Rosc1 koff ; (2)
to obtain kon (slope) ¼ 3.8 3 103 mM1 ms1 and koff
(y-intercept) ¼ 0.23 ms1 (Fig. 6 e). From these values
we calculated KD ¼ 60 mM, which is very close to the EC50
measured from the enhancement of late tail current (53 mM,
Fig. 2). Thus, these data are consistent with a model where
roscovitine binds to open channels to affect the kinetics.
Modeling roscovitine effects on N-current
We were interested in determining gating transitions that
could be affected by roscovitine to slow deactivation. Thus,
we generated several models to determine the simplest that
could reproduce our data. We have excluded inactivation
from these models since we currently do not have enough
data to model N-channel inactivation in either control or
roscovitine. The determination of roscovitine’s effect on in-
activation requires further study.
The ﬁrst models we investigated were those where
roscovitine bound with high afﬁnity (60 mM) to both closed
and open channels to affect C 4 O transitions. Some of
these models were able to reproduce much of our data, but
were unable to reproduce the envelope tail current data (Fig.
6). The next model type considered was one where roscovi-
tine bound to the open state and unbinding was required
before the channel could close (Scheme 1). Initially, all rate
constants in Scheme 1 were voltage-dependent, except for
voltage-independent k45 and k54. The primary problem with
this model was that tD in roscovitine would reach a limit at
negative potentials where O / C transitions became fast
relative to RO/ O, but no such limit was observed in our
recordings down to 180 mV. The tD limit was overcome
by making the roscovitine dissociation rate constant (k54)
voltage-dependent, but this model showed a voltage-
dependent EC50 for roscovitine binding which we do not
observe in our data (compare120 mV in Fig. 2 with170 mV
in Fig. 6). This led us to models where roscovitine could bind
to multiple states with different afﬁnities (Schemes 2 and 3).
For both schemes, the horizontal transitions are voltage-
dependent and the vertical transitions are roscovitine binding
and unbinding steps.
FIGURE 6 N-channels must open before roscovitine
can bind to affect deactivation kinetics. Currents
generated during a tail current envelope paradigm are
shown from the same cell in both control (A) and 100-
mM roscovitine (B). The 170 mV step durations
shown are 0.3, 0.8, 2.0, and 9.0 ms for both control and
roscovitine. Exponential ﬁts to the tail currents are
superimposed on the tail currents. These ﬁts were
single-exponential equations for control, whereas
double exponentials were used for tail currents in
roscovitine. The currents were recorded 30 mM Ba21.
(C) The amplitudes of the exponential ﬁts are plotted
versus step duration. These amplitudes were ﬁt to
a single exponential (after a 0.3-ms delay) to obtain an
estimate of the activation t for each component. For
control (open circles) the activation t was 0.4 ms. The
single-exponential ﬁt to control data was scaled (*0.4,
dashed line) to show that the fast deactivation com-
ponent (control-like tD, solid circles) in roscovitine
activated with the same time course as that in control.
The amplitude of this component peaked at;1 ms and
monotonically declined with longer step pulses. The
amplitude of the slowly deactivating current in
roscovitine (solid squares) increases monotonically
with step duration after a brief delay (;0.3 ms). These
data and their single-exponential ﬁt are replotted in D
along with data from 10- and 30-mM roscovitine to
illustrate the concentration-dependence of activation of
the slowly deactivating tails. The time constants for
each ﬁt are indicated. (E) A plot of the roscovitine-induced inverse envelope t versus roscovitine concentration is well ﬁt by a linear regression (see text). The
slope of this line is 0.0038 mM1 ms1 and the y-intercept is 0.23 ms1, which yields KD ¼ 60 mM. Data in A–D are from the same cell, and data in E are the
average of three cells.
SCHEME 1 [R] indicates roscovitine concentration.
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The control currents generated by both these models
compare very well with whole-cell N-current (Fig. 7).
Steady-state activation is better ﬁt by Scheme 2, but Scheme
3 better ﬁts the tD data. For both models, the tA measured
from simulated currents corresponds well at potentials #
0 mV with those from control whole-cell data, but at more
depolarized voltages the simulated currents activated faster
than whole-cell currents (Fig. 7 b). The whole-cell tA ap-
pears to approach an asymptote of ;0.4 ms at voltages
.130 mV. Consistent with this idea, the envelope tail
protocol using 170 mV steps yields tA ¼ 0.34 6 0.05 ms
(n ¼ 3) for control (Fig. 6 c). We currently do not know the
reason for this apparent tA asymptote, but one possibility is
that there is a voltage-independent transition on the pathway
to channel opening. Another possibility is that the transient
outward gating current obscures the true time-course of
channel activation at depolarized voltages where inward
currents are small. However, the limitation of current size
should be overcome by using the envelope tail protocol. Due
to the uncertainty regarding the apparent tA asymptote, the
models have not been adjusted to ﬁt tA at depolarized volt-
ages. Fortunately, this should not affect the ability of the
model to reproduce the roscovitine data, since roscovitine
does not affect the tA at V . 0 mV (Fig. 3 c).
Scheme 2 was the model we believed would reproduce
roscovitine’s effect on N-current. For this model roscovitine
preferentially binds to the open state (KD¼ 100 mM), but can
bind with low afﬁnity (KD ¼ 1 mM) to the neighboring
closed state. Thus, there would be little or no closed-state
binding at our test concentration (100 mM). This model
could reproduce fairly well the voltage dependence of steady-
state activation and tD (Fig. 7, a and c). The roscovitine-
induced shift in activation V1/2 was 2.3 mV vs. 4 mV and the
tD n in roscovitine was 70.4 mV compared to 59.2 mV
for Scheme 2 versus whole-cell data, respectively. Surpris-
ingly, we could not ﬁnd parameters that could reproduce both
the roscovitine EC50 and the effect on tA. The reason is that
these two parameters are inversely related in the model so
that parameters that reproduced the experimentally measured
EC50 (;50 mM) caused tA to become unacceptably large
(.6 ms at 20 mV), whereas parameters that reproduced tA
gave an unacceptably low EC50. The values presented for
Scheme 2 represent our best compromise (Table 1), where
both EC50 (117 mM) and tA (4 ms at 20 mV) are closest to
their measured values (Fig. 7). This inverse correlation
between roscovitine EC50 and tA in Scheme 2 appeared to
result from channels moving from C4/ O5 to replace those
moved from O5 to RO7. Thus, a higher EC50 reduced the
number of channels entering RO7, which reduced its
inﬂuence on tA. This led us to develop a model that would
reduce the effect of roscovitine binding on tA. This was
accomplished in Scheme 3 by linking the high afﬁnity
binding to a second open state (O5/ RO7). Scheme 3 was
slightly better than Scheme 2 at reproducing the roscovitine-
induced shift in the activation-voltage relationship and the tD
n. The shift in activation V1/2 was 3.7 mV (vs. 4 mV) and the
tD n was 51.0 mV (versus 59 mV) in roscovitine.
SCHEMES 2 and 3 The rate constant (A, s1) and charge moved (z) for
each transition are given in Table 1. The binding rate constants have units
of mM1 s1.
FIGURE 7 A model of roscovitine binding to open N-channels can
reproduce the whole-cell data. All solid lines are either experimental data or
ﬁts to that data (n ¼ 3–7 cells). The data from Scheme 2 simulations are
indicated by the open symbols and Scheme 3 simulation data are shown by
solid symbols. (A) The activation-voltage relationships measured from
simulated tail currents are nicely described by the major (80% of maximum
current) and steeper (slope¼ 7.1mV) component of double Boltzmann ﬁts to
whole-cell data (smooth lines). (B) Roscovitine slows activation of simulated
currents at hyperpolarized voltages. tA was from single-exponential ﬁts to
currents starting 0.3ms into the voltage step and is plotted versus step voltage.
For comparison, tA from whole-cell data is also shown (control, thin line;
roscovitine, thick line). (C) tD measured from simulated tail currents (10-ms
step to 150 mV, followed by 14-ms step to the tail voltage) are plotted for
control (squares) and 100-mM roscovitine (circles). The smooth lines are
single-exponential ﬁts to whole-cell tD-voltage relationship in both control
and 100-mM roscovitine. These ﬁts were obtained from tD averaged from
seven cells. (D) The inverse envelope t are plotted versus roscovitine
concentration. The solid line is the regression ﬁt to Scheme 3 simulated data
(solid circles), whereas the dashed line (long dashes) is the ﬁt to Scheme 2
simulated data (open circles). The indicatedKDwas calculated from the same
ﬁt parameters as in Fig. 6. The regression ﬁt from Fig. 6 E is superimposed
(short dashes) for comparison with the simulated data.
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However, the real beneﬁt of Scheme 3 was that it could
reproduce both the roscovitine EC50 (47 mM) and the effect
on tA (Fig. 7). Using the envelope tail current protocol, we
conﬁrmed that Scheme 3 could reproduce the open-state
binding parameters calculated from whole-cell current (Fig.
7 d). Scheme 3 was also able to reproduce the concentration-
dependent delay in slow tail activation (see Fig. 6 d, 10 mM
roscovitine). Since roscovitine binds to the open state, the
development of slow deactivation is both concentration- and
time-dependent. At low roscovitine concentrations (10 mM),
binding is sufﬁciently slow to generate a measurable delay to
detection of slow deactivation. Binding was rapid enough at
higher concentrations (e.g., 100 mM) that we could not detect
a delay in either simulated or recorded currents. Our model-
ing of roscovitine’s effect on N-current has revealed the
surprising possibility that N-channels gate with two open
states.
Action potential-induced currents
The physiological impact of slower N-channel deactivation
is the increase in Ca21 inﬂux during an action potential (AP).
Calcium channel activation is slow relative to that of sodium
channels so that peak calcium current is observed during the
repolarization phase of the AP (18,19). However, N-chan-
nels normally close before the after-hyperpolarization where
driving force is particularly large, which greatly limits the
amount of Ca21 that crosses the membrane. Thus, the Ca21
inﬂux through roscovitine-modiﬁed N-channels should be
greatly enhanced as a result of the reduced voltage depen-
dence of deactivation. Fig. 8 shows the effect of roscovitine
on N-current generated by an AP waveform along with
simulations using Scheme 3. Roscovitine greatly prolonged
N-current during the AP, but also inhibited the peak current
(Fig. 8 a). Both these effects were expected based on the
voltage-step data. Roscovitine also induced a slight right-
shift in peak current as expected from the slower activation.
This shift was small because tA is normalized at voltages
$0 mV (Fig. 3 c). The reduced voltage dependence of deac-
tivation results in complete N-current deactivation ;8 ms
after the AP peak compared to ;1 ms in control. Integration
of the AP-induced currents showed that roscovitine in-
creased Ca21 inﬂux by 39.26 6.1% (p, 0.01, n ¼ 4) even
though peak current was inhibited.
The simulated control current using Scheme 3 is very
similar to the whole-cell AP-induced currents (Fig. 8 b, thin
current traces). The current peaks at approximately the same
point during AP repolarization and is completely deactivated
by the start of the after-hyperpolarization phase. Roscovitine
induced a 17% increase in peak current (Fig. 8 b, dashed line
trace), a slight right shift in peak current, and a dramatic
increase in the duration of AP-induced current. This current
was reduced by 30% (Fig. 8 b, thick line trace) to facilitate
comparison with the whole-cell current, since roscovitine
induced an ;30% inhibition of whole-cell current in this set
of experiments. Complete deactivation of the simulated cur-
rent occurred ;7 ms after the AP peak, which is similar to
that observed with the whole-cell currents in roscovitine.
DISCUSSION
We have demonstrated that N-type calcium channels can
be modulated by roscovitine. The dominant effect is to
slow N-channel deactivation with relatively small effects on
the time-course and voltage-dependence of activation. The
slowed deactivation appears to result from roscovitine
TABLE 1 Rate parameters for Scheme 2 and 3 models
Scheme 2 Scheme 3
A z A z
k12 5000 0.9 5000 0.8
k21 1700 0.9 500 0.8
k23 4000 0.9 4000 0.9
k32 1700 0.9 500 0.9
k34 10,000 0.6 3000 0.9
k43 1000 0.6 250 0.9
k45 10,000 0.3 2000 0.6
k54 3000 0.3 1000 0.6
k46 2[R] — 4[R] —
k64 2000 — 4000 —
k57 2[R] — 4[R] —
k75 200 — 200 —
k67 10,000 0.3 2000 0.6
k76 300 0.3 50 0.6
A (s1) is the rate constant at the characteristic voltage (10 mV) and z is the
charge moved. [R] is the roscovitine concentration (mM). The units of A for
k46 and k57 are mM
1 s1.
FIGURE 8 Roscovitine increases the duration of AP-induced N-current.
(A) Whole-cell currents recorded before (thin trace) and during (thick trace)
application of 100-mM roscovitine. The initial outward current is gating
current that is activated during the rising phase of the AP. The gating current
has not been studied, but is likely generated by gating charge movement in
sodium, calcium, and potassium channels. The AP waveform used to
generate these currents is described in Materials and Methods. (B) Simulated
currents using Scheme 3. The control current is shown as a thin trace and
current in 100-mM roscovitine is shown as a dashed trace. The thick trace is
the roscovitine-modiﬁed current decreased by 30% to account for the
inhibitory action of roscovitine on the whole-cell current.
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binding to open channels, and Scheme 3 nicely reproduces
the effect of roscovitine on both activation and deactivation.
Yan et al. (1) showed similar effects of roscovitine on the
deactivation of vCMVIIC-sensitive calcium currents in rat
neostriatal neurons. These authors failed to observe a shift in
the activation-voltage relationship, but they used a lower
roscovitine concentration (50 mM vs. 100 mM) that may
have made such a shift more difﬁcult to observe. We also
failed to observe a shift when using 30-mM roscovitine
(not shown). It appears that a maximal roscovitine effect is
needed to observe the small shift (;4 mV) in the activation
curve.
Based on vCMVIIC sensitivity, Yan et al. (1) concluded
that P/Q-channels were the target of roscovitine, but micro-
molar vCMVIIC also blocks N-type channels (4). The
calcium current in the neostriatal neurons used by Yan et al.
(1) is comprised of ;35% L-type, ;25% N-type, ;20%
P/Q-type, and ;20% R-type current (20). Thus, L-type and
R-type channels appear to be relatively insensitive to
roscovitine, but either one or both of the vCMVIIC-sensitive
channels could be affected. The available evidence supports
the modulation of both N- and P/Q-type channels by
roscovitine (this article; see also Ref. 21; and unpublished
results). Tomizawa et al. (21) showed in the hippocampus
that roscovitine could enhance both the Ca21 inﬂux through
P/Q-channels and the rising phase of excitatory postsynaptic
potentials (characteristic of increased neurotransmitter re-
lease). The excitatory postsynaptic potential enhancement
was blocked by vAgaIVA (speciﬁc P/Q-channel blocker),
but not v-conotoxin GVIA (speciﬁc N-channel blocker). It is
not clear why N-channels did not participate in the enhanced
neurotransmitter release, but in our experiments 10-mM ros-
covitine as used by Tomizawa et al. (21) has only minor effects
on N-current (Fig. 2). Thus, it is possible that P/Q-channels
have a higher sensitivity to roscovitine.
Kinases are not involved in the roscovitine effect
Roscovitine inhibits several kinases including cdk 1, 2, and
5, extracellular signal-regulated kinase 1 and 2, and glycogen
synthase kinase 3 (2). However, the available evidence sup-
ports the idea that kinases are not involved in the roscovitine-
induced slowing of calcium channel deactivation. The evidence
includes the rapid onset of the roscovitine effect (#2 s),
the failure of intracellular roscovitine to modulate current,
and the inability of olomoucine to slow deactivation (1, Fig.
1). In addition, the roscovitine-induced slow deactivation
was observed in neurons isolated from mice lacking p35,
which is the neuron-speciﬁc activator of cdk5 (1). However,
cdk5 can phosphorylate the intracellular loop between
domains I and II of P/Q-channels (21). This phosphorylation
inhibits the binding of SNAP-25 and synaptotagmin to the
intracellular loop, but it is not clear what effect, if any, this
phosphorylation has on channel activity. Phosphorylation of
N-type channels by other serine/threonine kinases can affect
G-protein-mediated modulation of these channels, but
slowed deactivation has never been reported (22).
The N-channel models
Our goal in generating these models was to provide insights
into the roscovitine-induced modiﬁcation of channel gating.
Thus, we present the minimal model that allowed us to re-
produce the data. All of the models we tested featured open-
state roscovitine binding as dictated by the whole-cell data.
In the simplest model, slow deactivation resulted directly
from roscovitine unbinding (Scheme 1). However, this
resulted in a voltage-independent tD at hyperpolarized volt-
ages where roscovitine dissociation became rate-limiting.
We overcame this limitation by making roscovitine disso-
ciation voltage-dependent, but this model showed a voltage-
dependent EC50 that was not observed in our data. The
failure of these linear models led us to uncouple N-channel
deactivation from roscovitine dissociation, which was
accomplished by allowing roscovitine to bind to multiple
states (Schemes 2 and 3). Scheme 2 was the ﬁrst such model
that we tested, and it solved the problems of Scheme 1 by
allowing roscovitine-bound channels to close. In this model,
slow deactivation resulted from a combination of roscovitine
dissociation (at more depolarized voltages) and the smaller
closing rate constant (RO7 to RC6). However, we could
not ﬁnd a single set of parameters that would ﬁt both the
roscovitine EC50 and tA. As described above, the exces-
sively slow activation appears to result from the movement
of channels from O5 into the higher Po RO7, causing chan-
nels to move from C4 / O5 to reestablish the proper
equilibrium. This ﬁnal problem was addressed by allowing
roscovitine to bind only to open states as in Scheme 1, but an
additional open state was added with different roscovitine
afﬁnity so that dissociation would not limit N-channel deac-
tivation (Scheme 3). The unbinding rate constant for RO6/
O4 is 20 times larger (yielding KD ¼ 1000 mM) than that for
RO7/O5 (yielding KD ¼ 50 mM). This solved the problem
of excessively slow activation because roscovitine binding
primarily induced a redistribution of channels among open
states with relatively high Po. As a result of the relatively
high occupancy of O4 and O5, few channels moved from C3
to O4, which contributed only a small component to acti-
vation. Although this activation component was slow, it
was too small to greatly affect the time course of activation.
As a result, Scheme 3 was able to reproduce the effect of
roscovitine on activation and deactivation using parameters
that yielded a reasonable EC50.
Once bound, roscovitine appears to reduce a backward
rate constant to slow deactivation, but that alone cannot
explain the reduced voltage dependence of deactivation (n).
The models of Scheme 2 and Scheme 3 achieve this effect
by roscovitine changing the rate-limiting step for channel
closing from transitions with high charge movement to tran-
sitions that move less charge. In Scheme 2, roscovitine changes
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the rate-limiting step from C4/ C3 (z ¼ 0.6) to RO7/
RC6 (z ¼ 0.3). In Scheme 3 the rate-limiting step changes
from O4/ C3 (z ¼ 0.9) to RO7/ RO6 (z ¼ 0.6). By
reducing both the rate- and voltage-dependence of channel
closing, roscovitine greatly extends the voltage range over
which N-channels can be studied.
One prediction of Scheme 3 is that two open states will be
observed in single N-channel recording. Our previous single-
channel recordings provided evidence for only a single
N-channel open state within the main gating mode (called
high Po; see Ref. 23). An additional open state could be
observed, but it was attributed to a second gating mode (low
Po; see Ref. 23). Neurotransmitter inhibition introduced yet
another open state (Reluctant) (24). However, our more re-
cent recordings have surprised us by showing multiple com-
ponents in open time distributions from recordings of
N-channel activity that we have classiﬁed as high Po (based
on our previously published criteria). These data are con-
sistent with that of Colecraft et al. (25), who show two
components to the open time distribution for exogenously
expressed N-type and P/Q-type channels. Together these
results support the existence of two N-channel open states
that may be more easily distinguished in roscovitine.
We showed that inactivation was enhanced by roscovitine,
but excluded inactivation from the model. The primary
reason is that we currently do not have enough data on de-
velopment and recovery from inactivation to model this
process with conﬁdence. An interesting paradox raised by
our observations is that roscovitine appears to enhance
U-type (intermediate closed state) inactivation while prefer-
entially binding to the open state. Some possible explana-
tions are that 1), roscovitine remains bound after N-channels
close; 2), roscovitine induces an inactivation mechanism not
observed in control; and 3), U-type inactivation primarily
occurs from the ﬁrst (intermediate) open state (Scheme 3)
instead of intermediate closed states. Thus, roscovitine could
provide new insights into mechanisms of N-channel inacti-
vation.
Using roscovitine to study physiological effects
of enhanced calcium current
One problem with roscovitine as a calcium channel drug is
that it has higher afﬁnity for kinases than for calcium
channels, which complicates interpretation of its effects.
However, there are kinase inhibitors that do not affect calcium
channel gating (e.g., olomoucine), which can easily be used to
control for the kinase inhibitory effects of roscovitine. This
adds additional experimental complexity, but the protocols
are straightforward and the results easily interpreted. In
addition, other roscovitine-related compounds are likely to be
identiﬁed that will be more selective for calcium channels.
A separate issue is that roscovitine does not appear to
differentiate between N-type and P/Q-type channels (CaV2.2
and CaV2.1, respectively). In this respect, roscovitine is no
different than BayK 8644, which cannot differentiate be-
tween different L-type channels (i.e., CaV1.2, CaV1.3, or
CaV1.4; see Refs. 26 and 27). However, this has not pre-
vented investigators from using this drug. Moreover, CaV2
channels have speciﬁc toxins that permit one to determine
the contributions of N- and P/Q-current to any Ca21-
mediated effect.
Roscovitine increases the amount of Ca21 entering the cell
during an AP (Fig. 8), which is likely the mechanism by
which neurotransmitter release is increased (1,21). N-type
calcium channels are tuned to open during the falling phase
of the AP, but close before the potential becomes too hyper-
polarized. The closing is driven by the voltage dependence of
the open state (23), which ensures that the channels are not
open when the driving force on Ca21 inﬂux is extreme (e.g.,
80 mV during the after-hyperpolarization phase). Such
a large Ca21 inﬂux could overwhelm the intracellular Ca21
homeostasis, which could lead to neuronal death (28).
Roscovitine’s disruption of this ﬁnely tuned mechanism
could have both positive and negative effects. The increase
in neurotransmitter release could improve neuronal commu-
nication, but the increased intracellular Ca21 could induce
neuronal injury.
We thank Dr. Stephen W. Jones, Geoffrey G. Schoﬁeld, and Haoya Liang
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